Search
Rimiducid
go.drugbank.com/drugs/DB04974InvestigationalRimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. … [A187496,L9521] The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.
Lecithin
go.drugbank.com/drugs/DB15834InvestigationalA complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Mixtures: ONE A DAY TABLETCategories: Compounds used in a research, industrial, or household settingUbiquinone Q2
go.drugbank.com/drugs/DB08690ExperimentalCategories: Compounds used in a research, industrial, or household settingIroxanadine
go.drugbank.com/drugs/DB05444ExperimentalIt induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). … BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent.
Adecatumumab
go.drugbank.com/drugs/DB05006InvestigationalAdecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). … EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.
Galiximab
go.drugbank.com/drugs/DB04901InvestigationalGaliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
XL784
go.drugbank.com/drugs/DB04991InvestigationalXL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. … Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles.
Metacycline
go.drugbank.com/drugs/DB00931ApprovedA broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.
NP-50301
go.drugbank.com/drugs/DB05662ExperimentalIt is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor. … Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual